NEW YORK (GenomeWeb News) — US Genomics has signed an agreement with the Lahey Clinic to look at microRNAs and the development of urologic cancers, the company said today.
The company said that the Lahey Clinic will use US Genomics’ Trilogy 2020 molecule detection platform and its Direct miRNA assay to “develop more accurate prognoses” for patients suffering from bladder cancer and prostate cancer.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.

In Science this week: in vitro generation of human reproductive cells, and more.

Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.